Shyam Babu Prasad was asleep when the deluge struck his home. "All of a sudden, a wave about 15ft high hit our home and all of us were thrown by its force," Mr Prasad said. Mr Prasad said the water separated them.
Updated:
January 13, 2021 12:03 IST
A failure to investigate the conduct of the recent Covaxin phase-3 trial can affect the course of other studies under way
Share Article
AAA
A failure to investigate the conduct of the recent Covaxin phase-3 trial can affect the course of other studies under way
More than a decade since the human clinical trial of the human papilloma virus (HPV) vaccine it was controversial and carried out without proper consent on nearly 23,500 girls in the 10-14 age group in Vadodara, Gujarat and Khammam district of Andhra Pradesh and eight years after the Supreme Court of India slammed the government for slipping into “deep slumber” in addressing the “menace” of illegal clinical trials carried out in India by multinational countries, nothing much seems to have changed.
Gagandeep Kang at CMC Hospital, Vellore.
| Photo Credit:
C. Venkatachalapathy
Even without missteps we have misinformation, warns the virologist, and any doubts can be blown up into larger conspiracy theories
A year after the outbreak of the novel coronavirus, which has claimed 1.8 million lives so far, scientists, manufacturers and drug regulators the world over have been speeding up the timelines for the development, testing and approval of vaccines for emergency use. Three safe and efficacious vaccines from Pfizer, Moderna and AstraZeneca have already been greenlighted.
In India, the Hyderabad-based Bharat Biotech has been working feverishly to develop and test a COVID-19 vaccine, Covaxin, that uses a time-tested inactivated vaccine platform; but the haste shown by the Indian drug regulator to approve it in the absence of efficacy data has taken the shine off an indigenously developed lifesaver. We speak to Gagandeep Kang, Professor of Microbiology at Christian Medical C